Rhumbline Advisers lifted its stake in shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP – Free Report) by 40.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,358 shares of the company’s stock after purchasing an additional 4,109 shares during the period. Rhumbline Advisers’ holdings in Rapport Therapeutics were worth $144,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of RAPP. TRV GP V LLC bought a new stake in Rapport Therapeutics during the 4th quarter valued at $126,579,000. TRV GP VI LLC bought a new position in shares of Rapport Therapeutics during the fourth quarter valued at about $17,194,000. Price T Rowe Associates Inc. MD grew its stake in shares of Rapport Therapeutics by 9.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,143,384 shares of the company’s stock valued at $20,285,000 after buying an additional 95,976 shares during the last quarter. Norges Bank bought a new position in shares of Rapport Therapeutics during the fourth quarter valued at about $860,000. Finally, Crestline Management LP purchased a new stake in shares of Rapport Therapeutics during the fourth quarter worth about $488,000.
Rapport Therapeutics Trading Down 5.3%
NASDAQ:RAPP opened at $11.73 on Thursday. Rapport Therapeutics, Inc. has a 12 month low of $6.43 and a 12 month high of $29.74. The company has a market cap of $428.15 million and a PE ratio of -3.40. The company has a 50 day simple moving average of $10.88 and a two-hundred day simple moving average of $12.66.
Analyst Ratings Changes
A number of analysts have recently weighed in on RAPP shares. JMP Securities began coverage on shares of Rapport Therapeutics in a report on Tuesday, April 8th. They set a “market outperform” rating and a $28.00 target price for the company. Citizens Jmp initiated coverage on shares of Rapport Therapeutics in a report on Tuesday, April 8th. They set a “mkt outperform” rating for the company. Four analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $32.67.
View Our Latest Analysis on Rapport Therapeutics
About Rapport Therapeutics
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Stories
- Five stocks we like better than Rapport Therapeutics
- 3 Healthcare Dividend Stocks to Buy
- Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
- Upcoming IPO Stock Lockup Period, Explained
- Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
- How to Capture the Benefits of Dividend Increases
- ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
Want to see what other hedge funds are holding RAPP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rapport Therapeutics, Inc. (NASDAQ:RAPP – Free Report).
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.